{"drugs":["Colistimethate Sodium","Coly-Mycin M","Coly-Mycin M Parenteral"],"mono":{"0":{"id":"133390-s-0","title":"Generic Names","mono":"Colistimethate Sodium"},"1":{"id":"133390-s-1","title":"Dosing and Indications","sub":[{"id":"133390-s-1-4","title":"Adult Dosing","mono":"<ul><li>each vial containing colistimethate sodium (pentasodium colistin-methanesulfonate) is equivalent to 150 mg of colistin base activity; colistin base 1 mg = colistimethate sodium 2.4 mg OR 30,000 International Units; colistimethate sodium 1 mg = 12,500 International Units<\/li><li><b>Disease due to Gram-negative bacteria, Pseudomonas aeruginosa, Enterobacter aerogenes, Escherichia coli, and Klebsiella pneumoniae:<\/b> 2.5 to 5 mg\/kg per day of colistin base IM or IV in 2 to 4 divided doses, depending on severity of infection; MAX 5 mg\/kg\/day based on colistin base activity<\/li><\/ul>"},{"id":"133390-s-1-5","title":"Pediatric Dosing","mono":"<ul><li>each vial containing colistimethate sodium (pentasodium colistin-methanesulfonate) is equivalent to 150 mg of colistin base activity; colistin base 1 mg = colistimethate sodium 2.4 mg OR 30,000 International Units; colistimethate sodium 1 mg = 12,500 International Units<\/li><li><b>Disease due to Gram-negative bacteria, Pseudomonas aeruginosa, Enterobacter aerogenes, Escherichia coli, and Klebsiella pneumoniae:<\/b> 2.5 to 5 mg\/kg per day of colistin base IM or IV in 2 to 4 divided doses, depending on severity of infection; MAX 5 mg\/kg\/day based on colistin base activity<\/li><\/ul>"},{"id":"133390-s-1-6","title":"Dose Adjustments","mono":"<ul><li>renal impairment (adults), mild (CrCl 50 to 79 mL\/min), 2.5 to 3.8 mg\/kg\/day of colistin base IM or IV in 2 divided doses<\/li><li>renal impairment (adults), moderate (CrCl 30 to 49 mL\/min), 2.5 mg\/kg\/day of colistin base IM or IV once daily or in 2 divided doses<\/li><li>renal impairment (adults), severe (CrCl 10 to 29 mL\/min), 1.5 mg\/kg\/day of colistin base IM or IV every 36 hours<\/li><li>obesity, determine dose based on ideal body weight<\/li><\/ul>"},{"id":"133390-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Disease due to Gram-negative bacteria, Pseudomonas aeruginosa, Enterobacter aerogenes, Escherichia coli, and Klebsiella pneumoniae<br\/>"}]},"3":{"id":"133390-s-3","title":"Contraindications\/Warnings","sub":[{"id":"133390-s-3-9","title":"Contraindications","mono":"history of sensitivity to colistimethate or its components <br\/>"},{"id":"133390-s-3-10","title":"Precautions","mono":"<ul><li>Clostridium difficile-associated diarrhea, including mild diarrhea to fatal colitis, has been reported; may occur more than 2 months after administration; if suspected or confirmed, discontinue any ongoing antibiotic therapy<\/li><li>inhalation therapy; acute respiratory failure may result when reconstituted colistimethate solution is not used promptly; after reconstitution, colistimethate is hydrolyzed to form active components, including polymyxin E1, which has shown to cause localized inflammation of the airway epithelia and eosinophilic infiltration<\/li><li>nephrotoxicity; reversible and dose-dependent manifestations may occur<\/li><li>neurological disturbances, transient (eg, circumoral paresthesia or numbness, tingling or formication of the extremities, generalized pruritus, vertigo, dizziness, and slurring of speech), may occur; dosage adjustment may be necessary<\/li><li>renal impairment; increased risk of apnea and neuromuscular blockade; dosage adjustment recommended<\/li><li>respiratory arrest has been reported after IM administration<\/li><\/ul>"},{"id":"133390-s-3-11","title":"Pregnancy Category","mono":"C (FDA)<br\/>"},{"id":"133390-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"133390-s-4","title":"Drug Interactions","sub":{"1":{"id":"133390-s-4-14","title":"Major","mono":"<ul><li>Amikacin (theoretical)<\/li><li>Capreomycin (theoretical)<\/li><li>Gentamicin (theoretical)<\/li><li>Kanamycin (theoretical)<\/li><li>Neomycin (theoretical)<\/li><li>Paromomycin (theoretical)<\/li><li>Streptomycin (theoretical)<\/li><li>Tobramycin (theoretical)<\/li><\/ul>"},"2":{"id":"133390-s-4-15","title":"Moderate","mono":"<ul><li>Alcuronium (probable)<\/li><li>Atracurium (probable)<\/li><li>Cisatracurium (probable)<\/li><li>Doxacurium (probable)<\/li><li>Fazadinium (probable)<\/li><li>Gallamine (probable)<\/li><li>Hexafluorenium (probable)<\/li><li>Metocurine (probable)<\/li><li>Mivacurium (probable)<\/li><li>Pancuronium (probable)<\/li><li>Pipecuronium (probable)<\/li><li>Rapacuronium (probable)<\/li><li>Rocuronium (probable)<\/li><li>Tubocurarine (probable)<\/li><li>Vecuronium (probable)<\/li><\/ul>"}}},"5":{"id":"133390-s-5","title":"Adverse Effects","mono":"<b>Serious<\/b><ul><li><b>Gastrointestinal:<\/b>Clostridium difficile diarrhea<\/li><li><b>Neurologic:<\/b>Neurological muscular paralysis<\/li><li><b>Renal:<\/b>Nephrotoxicity (31%)<\/li><li><b>Respiratory:<\/b>Respiratory failure, Respiratory tract paralysis<\/li><\/ul>"},"6":{"id":"133390-s-6","title":"Drug Name Info","sub":{"0":{"id":"133390-s-6-17","title":"US Trade Names","mono":"<ul><li>Coly-Mycin M<\/li><li>Coly-Mycin M Parenteral<\/li><\/ul>"},"2":{"id":"133390-s-6-19","title":"Class","mono":"Antibiotic<br\/>"},"3":{"id":"133390-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"133390-s-6-21","title":"Generic Availability","mono":"Yes<br\/>"}}},"7":{"id":"133390-s-7","title":"Mechanism Of Action","mono":"Colistimethate sodium, a polypeptide antibiotic, penetrates and disrupts the bacterial cell membrane of susceptible strains of aerobic gram-negative bacteria.<br\/>"},"8":{"id":"133390-s-8","title":"Pharmacokinetics","sub":[{"id":"133390-s-8-23","title":"Absorption","mono":"<ul><li>Tmax, IM: 1 to 2 hour<\/li><li>Tmax, IV: 30  to 60 minutes<\/li><li>Bioavailability, Oral: not absorbed<\/li><li>Bioavailability, IM: well-absorbed<\/li><\/ul>"},{"id":"133390-s-8-24","title":"Distribution","mono":"<ul><li>Vd, cystic fibrosis: 0.34 L\/kg<\/li><li>Vd, renal failure: 10.9 L  to 27 L<\/li><\/ul>"},{"id":"133390-s-8-25","title":"Metabolism","mono":"<ul><li>Plasma: 31.2% hydrolyzed to sulfomethylated derivatives and colistin<\/li><li>Colistin: active<\/li><\/ul>"},{"id":"133390-s-8-26","title":"Excretion","mono":"<ul><li>Renal: approximately 60% unchanged<\/li><li>Dialyzable: Unknown (hemodialysis)<\/li><li>Dialyzable: Yes (peritoneal), insignificant amount<\/li><li>Hemofiltration: Yes, 20.3% colistimethate sodium, 6.88% colistin<\/li><li>Total body clearance, critically ill: 0.26 L\/hr\/kg<\/li><li>Total body clearance, cystic fibrosis: 2 mL\/min\/kg<\/li><\/ul>"},{"id":"133390-s-8-27","title":"Elimination Half Life","mono":"<ul><li>Adults, children, 2 to 3 hour<\/li><li>Renal impairment, up to 2 to 3 days<\/li><\/ul>"}]},"9":{"id":"133390-s-9","title":"Administration","mono":"<ul><li><b>General Information<\/b><br\/><ul><li>reconstitute 150 mg (colistin base) vial with 2 mL sterile water for injection for a resulting concentration of 75 mg\/mL colistin base; swirl gently to avoid frothing<\/li><li>IV administration is preferred because of severe pain at the injection site caused by IM administration<\/li><\/ul><\/li><li><b>Inhalation<\/b><br\/>administer inhalation treatment promptly after colistimethate for injection is reconstituted; storing colistimethate aqueous solution for longer than 24 hours increases colistin concentration and increases the potential for lung toxicity<br\/><\/li><li><b>Intramuscular<\/b><br\/><ul><li>administer by deep IM injection into large muscle mass (eg, gluteal muscles or lateral portion of thigh)<\/li><li>IV administration is preferred over IM administration.<\/li><\/ul><\/li><li><b>Intravenous<\/b><br\/><ul><li>(continuous infusion) slowly inject one-half of the total daily dose over 3 to 5 minutes; add remaining half to NS, D5NS, D5W, D5-0.45%NaCl, D5-0.225%NaCl, LR, or 10% invert sugar solution and infuse over 22 to 23 hours, starting 1 to 2 hours after initial dose; decrease infusion rate based on degree of renal impairment; use infusion solution within 24 hours<\/li><li>(direct intermittent administration) slowly inject one-half of the total daily dose over 3 to 5 minutes every 12 hours<\/li><\/ul><\/li><\/ul>"},"10":{"id":"133390-s-10","title":"Monitoring","mono":"<ul><li>cultures and sensitivities<\/li><li>CBC<\/li><li>symptomatic improvement<\/li><li>temperature<\/li><li>renal function<\/li><li>signs and symptoms of neuromuscular blockade<\/li><\/ul>"},"11":{"id":"133390-s-11","title":"How Supplied","mono":"<ul><li><b>Generic<\/b><br\/>Injection Powder for Solution: 150 MG<br\/><\/li><li><b>Coly-Mycin M Parenteral<\/b><br\/>Injection Powder for Solution: 150 MG<br\/><\/li><\/ul>"},"13":{"id":"133390-s-13","title":"Clinical Teaching","mono":"<ul><li>Advise patient against driving or performing hazardous tasks during therapy, as drug can cause tingling of extremities, vertigo, or dizziness.<\/li><li>Instruct patient to report watery or bloody diarrhea during therapy or up to several weeks post-therapy, and consult with healthcare professional prior to taking antidiarrheal medicine.<\/li><li>Drug may cause rash, fever, gastrointestinal disturbances or transient neurological symptoms (circumoral paresthesia or numbness, pruritus, slurred speech).<\/li><li>Instruct patient to report symptoms of nephrotoxicity, decreased urinary output, or respiratory distress.<\/li><\/ul>"}}}